阿法替尼联合吉西他滨对比吉西他滨单药一线治疗转移性胰腺癌:随机开放标签II期ACCEPT研究及「治疗负担」方法整合分析
结果显示两组中位OS分别为7.3个月和7.4个月(HR 1.06,p=0.80),中位PFS均为3.9个月(HR 0.85,p=0.43),联合组不良事件更频繁,BOTh©™分析显示联合组治疗毒性负担显著更高(p=0.0005)。
要点
- 阿法替尼联合吉西他滨未改善转移性胰腺癌患者的总生存期和无进展生存期。
- 联合组腹泻(71% vs 13%)和皮疹(65% vs 5%)发生率明显高于单药组。
- BOTh©™方法可量化评估治疗相关毒性负担,联合组显著更高(p=0.0005)。
核心结论
- 在转移性胰腺癌一线治疗中,吉西他滨基础上加用阿法替尼未提高疗效且毒性增加。
研究设计与样本
- 吉西他滨剂量为1000 mg/m2每周一次连续三周休息一周,每四周重复;阿法替尼为40 mg口服每日一次。
- 主要研究终点为总生存期(OS),并采用BOTh©™方法量化每位患者每日的治疗负担/毒性。
主要发现
- 联合组与单药组中位OS分别为7.3个月和7.4个月(HR 1.06,p=0.80)。
- 两组中位无进展生存期均为3.9个月(HR 0.85,p=0.43)。
- 联合组不良事件更频繁,腹泻发生率为71% vs 13%,皮疹为65% vs 5%。
- BOTh©™分析显示联合组治疗毒性负担显著更高(p=0.0005)。
临床怎么用
- 不推荐在转移性胰腺癌一线治疗中常规联合阿法替尼与吉西他滨。
- 临床决策时应重视联合方案带来的腹泻和皮疹等毒性负担增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeting the epidermal growth factor receptor pathway remains controversial in pancreatic cancer. Afatinib is an oral irreversible ErbB family blocker approved in non-small-cell lung cancer. This open-label, multicenter, randomised phase II trial evaluated gemcitabine plus afatinib (Gem/afatinib) versus gemcitabine (Gem) alone as first-line treatment for metastatic pancreatic cancer. PATIENTS AND METHODS: Patients were randomised in a 2:1 ratio to either Gem (1000 mg/m2 weekly for three weeks followed by one week of rest, repeated every four weeks) and afatinib (40 mg orally once daily) or Gem alone. Overall survival (OS) was the primary study end-point. The novel BOTh©™ methodology was implemented to derive a quantitative estimate for the 'Burden of Therapy/Toxicity' (BOTh) for each patient on every day during the clinical study. RESULTS: One hundred nineteen patients from 25 centres were randomised, 79 patients for Gem/afatinib and 40 for Gem. Median OS was 7.3 months in the Gem/afatinib arm versus 7.4 months in the Gem-alone arm (hazard ratio [HR]: 1.06, p = 0.80). Median progression-free survival was identical in both arms (3.9 months versus 3.9 months, HR: 0.85, p = 0.43). Adverse events were more frequent in the Gem/afatinib arm, especially diarrhoea (71% vs. 13%) and skin rash (65% vs. 5%). The BOTh©™ analysis revealed a significantly higher burden of toxicity in the combination arm (p = 0.0005). CONCLUSION: The addition of afatinib to Gem did not improve treatment efficacy and was more toxic. The BOTh©™ methodology allowed a detailed insight into the course of treatment-related adverse events over the study period. The trial was registered at clinicaltrials.gov (NCT01728818) and Eudra-CT (2011-004063-77).
引用
- Haas M, Waldschmidt DT, Stahl M, et al. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method. Eur J Cancer. 2021. PMID: 33588150. doi:10.1016/j.ejca.2020.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。